New hope for rare autoimmune disease: baricitinib trial underway

NCT ID NCT05300932

Ongoing Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 4 trial tests whether baricitinib, a drug already used for rheumatoid arthritis, can help people with systemic sclerosis—a rare disease that causes skin thickening and organ damage. Sixty participants will receive either baricitinib or standard treatment for 24 weeks, then all will take baricitinib for another 24 weeks. The main goal is to see if baricitinib reduces skin thickness better than current therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Baricitinib (Olumiant)
What this could lead to: If it works, baricitinib could offer a new treatment option to control skin fibrosis and other symptoms in systemic sclerosis.
What could go wrong: This is a small, early-phase trial with only 60 participants. Baricitinib may not prove more effective than standard care, and side effects like infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse cutaneous systemic sclerosis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC SCLEROSIS

Contacts and locations

Locations

Department of RheumatologyTongji Hospital

Wuhan, Hubei, 430030, China
Tongji Hospital

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.